Navigation Links
Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
Date:7/9/2013

SANTA CLARA, Calif., July 9, 2013 /PRNewswire/ -- NextBio, whose Big Data technology enables users to apply genomic data from disparate sources in novel and useful ways across life sciences research, today announced that Boehringer Ingelheim has signed a multi-year renewal agreement to the NextBio Research Platform. The new agreement also expands the user base for NextBio across Boehringer Ingelheim's global research organization.

(Logo: http://photos.prnewswire.com/prnh/20130402/SF86976LOGO)

"Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies and has been a user of NextBio Research for the past year," said Saeid Akhtari, NextBio President and Chief Executive Officer. "This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology's value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide.

"NextBio Research provides a comprehensive platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research," Mr. Akhtari added. "Integrating proprietary analysis results with extensive curated content, NextBio enhances researchers' ability to design experiments, test hypotheses and validate results, leading to better target analysis, understanding of disease mechanisms, and analysis of results across species."

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high the
'/>"/>

SOURCE NextBio
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
2. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
3. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
4. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
6. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
7. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
8. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
9. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
10. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
11. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:4/24/2014)... professor in the new Institute for Biomedical Sciences ... $2.83 million federal grant to develop novel therapeutics ... grant from the Eunice Kennedy Shriver National Institute ... National Institutes of Health will support Plemper,s drug ... at least one distinct alternative compound. , Infections ...
(Date:4/24/2014)... to give than to receive at least if you,re ... , The study found that 15- and 16-year-olds who find ... family members, are less likely to become depressed than those ... the money for themselves. , The researchers detail their findings ... . , The study focused on the ventral striatum, a ...
(Date:4/24/2014)... pH1N1 virus caused the first flu pandemic in the ... and killed more than 50 people in the country. ... flu epidemics (winter/spring seasons). , Infections with influenza ... World Health Organization has recommended Tamiflu for treatment of ... this drug is that it targets viral proteins which ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... to high-energy particles, simulating conditions astronauts would face on ... and slower reaction times, even when the radiation exposure ... impairments which affected a large subset, but far ... linked to protein changes in the brain, the scientists ... humans, suggest it may be possible to develop a ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... in the cereal category as they provide fibre beta glucan ... health-conscious consumers. So there is news to cheer now as ... called beta-glucan in their diets.,This variety of oats has been ... University (NDSU) scientists., ,Beta-glucan can help lower blood levels ...
... A new study has found that at high doses, ... result in liver damage, leading to significant health risks. ... University of Toronto, results of which can be found ... ,Previous studies have demonstrated the anti-oxidant effects of ...
... found out that retinal examination of a child, to determine the ... of abuse. // This was discussed in the American Academy of ... is a light sensitive tissue located behind the eye. Any rupture ... the result is bleeding or retinal hemorrhage. , A ...
... a molecular computer, which uses enzymes to perform calculations ... release of drugs.// ,Itamar Willner, who built ... Jerusalem in Israel, said the enzyme-powered computers could have ... future, be implanted into humans. ,The researchers ...
... California was slapped with four additional law suits, after the ... miserably. // ,Orange county Superior court has ... of patients who died just waiting for the transplants; the ... ,The liver transplant program transparent to gross mismanagement has to ...
... of doctors at the U.S. military prison in Guantanamo ... strike) through insertion of feeding tubes // through their ... who claim that such practices violate the fundamental principles ... are being subjected to harsh interrogations, targeted at extension ...
Cached Medicine News:Health News:Retinal Hemorrhage: No More a Sure Sign of Child Abuse 2Health News:Medical Ethics Violated By Prison Officials In Guantanamo Bay 2
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
... less than thirty pounds, the EUB 405 ... quality. Compatible with a wide range of ... solution for a variety of clinical settings. ... easy to operate. It includes an alphanumeric ...
... The HI VISION 6500 ... offers advanced clinical imaging, enhanced ... flexibility, all in robust and ... a better clinical solution in ...
... The PENTAX FG-36UX provides a wide range ... It is also possible to obtain a clear ... Flow Mapping and Color Flow Angio. An accessory ... has improved. Those feature make it possible for ...
Medicine Products: